Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIEW-1201 (povidone-iodine) in adenoviral conjunctivitis
NCT03749317Phase 2Completed
- Sponsor
- IVIEW Therapeutics Inc.
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of povidone-iodine in adenoviral conjunctivitis (2 arms), sponsored by IVIEW Therapeutics Inc. Primary endpoint: Clinical resolution by assessment of bulbar conjunctival injection and watery conjunctival discharge at Day 6. Started Feb 2023; status: completed.
02
Drugs
povidone-iodine
03
Conditions
adenoviral conjunctivitis
Beyond the preview
Go deeper on NCT03749317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749317.